Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Receives Average Recommendation of “Moderate Buy” from Analysts

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) has been given an average recommendation of “Moderate Buy” by the nine research firms that are covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have issued a buy recommendation and two have issued a strong buy recommendation on the company.

BAYRY has been the topic of several recent analyst reports. Zacks Research downgraded shares of Bayer Aktiengesellschaft from a “hold” rating to a “strong sell” rating in a report on Tuesday, March 24th. DZ Bank raised Bayer Aktiengesellschaft from a “strong sell” rating to a “hold” rating in a research report on Thursday, April 9th. Finally, UBS Group upgraded Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a research note on Monday, March 16th.

Bayer Aktiengesellschaft Stock Down 0.0%

Shares of Bayer Aktiengesellschaft stock opened at $10.86 on Friday. Bayer Aktiengesellschaft has a 12-month low of $6.20 and a 12-month high of $14.85. The company has a quick ratio of 0.63, a current ratio of 1.01 and a debt-to-equity ratio of 1.22. The stock has a 50 day moving average price of $11.37 and a two-hundred day moving average price of $10.87. The stock has a market capitalization of $42.68 billion, a P/E ratio of -9.78 and a beta of 0.62.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last released its quarterly earnings results on Wednesday, March 4th. The company reported $0.18 EPS for the quarter, meeting analysts’ consensus estimates of $0.18. The company had revenue of $13.24 billion for the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft had a negative net margin of 8.51% and a positive return on equity of 15.93%. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. Equities analysts expect that Bayer Aktiengesellschaft will post 1.2 earnings per share for the current year.

Bayer Aktiengesellschaft Company Profile

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.